Renal effects of urodilatin in healthy subjects are independent of blockade of the cyclooxygenase and angiotensin II receptor

References

• Schulz‐Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R., Forssmann W. G. Isolation and structural analysis of urodilatin, a new peptide of the cardiodilatin‐(ANP)‐family, extracted from human urine. Klin Wochenschr 1988; 6: 752–59
   Google Scholar
• Greenwald J. E., Ritter D., Tetens E., Rotwein P. S. Renal expression of the gene for atrial natriuretic factor. Am J Physiol 1992; 262: F974–8
   Google Scholar
• Saxenhofer H., Fitzgibbon W. R., Paul R. V. Urodilatin: binding properties and stimulation of cGMP generation in rat kidney cells. Am J Physiol 1993; 264: F267–73
   PubMed Web of Science ®Google Scholar
• Drummer C., Fiedler F., König A., Gerzer R. Urodilatin, a kidney‐derived natriuretic factor, is excreted with a circadian rhythm and is stimulated by saline infusion in man. J Am Soc Nephrol 1991; 1: 1109–13
   PubMed Web of Science ®Google Scholar
• Saxenhofer H., Rashelli A., Weidmann P., Forssmann W. G., Bub A., Ferrari P., et al. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990; 259: F832–F838
   PubMed Web of Science ®Google Scholar
• Carstens J., Jensen K. T., Pedersen E. B. Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Clin Sci 1997; 92: 397–407
   Google Scholar
• Carstens J., Greisen J., Jensen K. T., Vilstrup H., Pedersen E. B. Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. J Am Soc Nephrol 1998; 9: 1489–98
   PubMedGoogle Scholar
• Carstens J., Jensen K. T., Pedersen E. B. Metabolism and action of urodilatin infusion in healthy volunteers. Clin Pharmacol Ther 1998; 64: 73–86
   PubMedGoogle Scholar
• Shima M., Seino Y., Torikai S., Imai M. Intrarenal localization of degradation of atrial natriuretic peptide: in isolated glomeruli and cortical nephron segments. Life Sci 1988; 43: 357–63
   PubMedGoogle Scholar
• Carstens J., Jensen K. T., Ivarsen P., Rasmussen L. M., Pedersen E. B. Development of a urodilatin‐specific antibody and radioimmunoassay for urodilatin in human urine. Clin Chem 1997; 43: 638–43
   PubMedGoogle Scholar
• Feller S., Gagelmann M., Forssmann W. G. Urodilatin: a newly described member of the ANP family. Trends Pharmacol Sci 1989; 10: 93–4
   PubMed Web of Science ®Google Scholar
• Carstens J., Gronbaek H., Larsen H. K., Pedersen E. B., Vilstrup H. Effects of urodilatin on natriuresis of cirrhosis patients with sodium retention. BMC Gastroenterol 2007; 7: 1–9
   PubMedGoogle Scholar
• Conlin P. R., Dluhy R. G., Williams G. H. Disorders of the renin‐angiotensin‐aldosterone system. Renal and electrolyte disorders, R. W Schrier. Lippincott‐Raven, Philadelphia 1997; 349–92
   Google Scholar
• Abraham W. T., Schrier R. W. Renal sodium excretion, edematous disorders and diuretic use. Renal and electrolyte disorders, R. W Schrier. Lippincott‐Raven, Philadelphia 1997; 72–129
   Google Scholar
• Mogensen C. E. Glomerular filtration rate and renal plasma flow in short‐term and long‐term juvenile diabetes mellitus. Scand J Clin Lab Invest 1971; 28: 91–100
   PubMed Web of Science ®Google Scholar
• Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984; 37: 217–23
   PubMed Web of Science ®Google Scholar
• Kappelgaard A. M., Nielsen M. D., Giese J. Measurement of angiotensin II in human plasma: Technical modification and practical experience. Clin Chim Acta 1976; 67: 299–306
   PubMed Web of Science ®Google Scholar
• Rask‐Madsen J., Bruunsgaard A., Munck O., Nielsen M. D., Worming H. The significance of bile acids and aldosterone for the electrical hyperpolarization of human rectum in obese patients treated with intestinal by‐pass operation. Scand J Gastroenterol 1974; 9: 417–26
   PubMed Web of Science ®Google Scholar
• Saxenhofer H., Raselli A., Weidmann P., Forssmann W. G., Bub A., Ferrari P., et al. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990; 259: F832–38
   PubMed Web of Science ®Google Scholar
• Brenner B. M., Ballermann B. J., Gunning M. E., Zeidel M. L. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990; 70: 665–99
   PubMed Web of Science ®Google Scholar
• Burnier M., Hagman M., Nussberger J., Biollaz J., Armagnac C., Brouard R., et al. Short‐term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25: 602–9
   PubMed Web of Science ®Google Scholar
• Burnier M., Rutschmann B., Nussberger J., Versaggi J., Shahinfar S., Waeber B., et al. Salt‐dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339–47
   PubMed Web of Science ®Google Scholar
• Riegger G. A. J., Elsner D., Forssmann W. G., Kromer E. P. Effects of ANP‐(95‐126) in dogs before and after induction of heart failure. Am J Physiol 1990; 259: H1643–8
   Google Scholar
• Frölich J. C., Hollifield J. W., Dormois J. C., et al. Suppression of plasma renin activity by indomethacin in man. Circ Res 1976; 39: 447–52
   PubMed Web of Science ®Google Scholar
• Kurtz A., Della Bruna R., Pfeilschifter J., Taugner R., Bauer. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP mediated process. Proc Natl Acad Sci USA 1986; 83: 4769–73
   PubMed Web of Science ®Google Scholar
• Fricker A. F., Nussberger J., Meilenbrock S., Brunner H. R., Burnier M. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int 1998; 54: 2089–97
   PubMed Web of Science ®Google Scholar
• Catella‐Lawson F., McAdam B., Morrison B. W., Kapoor S., Kujubu D., Antes L., et al. Effects of specific inhibition of cyclooxygenase‐2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735–41
   PubMed Web of Science ®Google Scholar
• Stichtenoth D. O., Marhauer V., Tsikas D., Gutzki F‐M., Frölich J. C. Effects of specific COX‐2‐inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 2005; 68: 2197–207
   PubMedGoogle Scholar
• Vervoort G., Hertenberg F., Wetzels J. F., Smits P. Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. J Hypertens 1998; 16: 245–50
   PubMedGoogle Scholar